Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2020 08/05/2020 08/06/2020 08/07/2020 08/10/2020 Date
276.08(c) 276.17(c) 277.66(c) 305.71(c) 299.97 Last
1 100 966 903 110 756 553 4 454 612 1 050 154 Volume
-0.75% +0.03% +0.54% +10.10% -1.88% Change
More quotes
Financials (USD)
Sales 2020 14 016 M - -
Net income 2020 5 361 M - -
Net cash position 2020 207 M - -
P/E ratio 2020 9,39x
Yield 2020 -
Sales 2021 13 176 M - -
Net income 2021 4 802 M - -
Net cash position 2021 3 340 M - -
P/E ratio 2021 10,1x
Yield 2021 -
Capitalization 48 398 M 48 398 M -
EV / Sales 2020 3,44x
EV / Sales 2021 3,42x
Nbr of Employees 7 400
Free-Float 86,4%
More Financials
Company
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (79.2%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (15.9%); - other (4.9%): primarily revenues from partnership agreements. 
More about the company
Surperformance© ratings of Biogen Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN INC.
06:01aBIOGEN : FDA Accepts Biogen's Aducanumab Biologics License Application for Alzhe..
AQ
08/07Roche-PTC Therapeutics' oral spinal muscular atrophy drug wins FDA approval
RE
08/07U.S. FDA approves Roche, PTC Therapeutics' spinal muscular atrophy drug
RE
08/07FDA Accepts Biogen's Aducanumab Biologics License Application for Alzheimer's..
GL
08/07BIOGEN : and Denali to Collaborate on LRRK2 Program for Parkinson's disease and ..
AQ
08/06BIOGEN : to Buy Stake in Denali for $465 Million as Part of Agreement to Develop..
DJ
08/06Biogen and Denali to Collaborate on LRRK2 Program for Parkinson's Disease and..
GL
07/28BIOGEN : Correction to Biogen Better-Than-Expected 2Q Adjusted Profit Article on..
DJ
07/27Biogen to Present Data at Virtual 2020 Alzheimer's Association International ..
AQ
07/24Biogen to Present Data at Virtual 2020 Alzheimer's Association International ..
GL
07/22BIOGEN : Management's Discussion and Analysis of Financial Condition and Results..
AQ
07/22Eisai to present latest data on pipeline assets in the area of alzheimer's di..
AQ
07/22BIOGEN : Plans to Initiate Phase 4 study Evaluating Benefit of SPINRAZA in Patie..
AQ
07/22BIOGEN : lifts full-year profit forecast as Tecfidera boosts quarter
RE
07/22GLOBAL MARKETS LIVE: Snap, Microsoft, Tesla…
More news
News in other languages on BIOGEN INC.
06:01aBIOGEN : FDA Accepts Biogen's Aducanumab Biologics License Application for Alzhe..
04:24aROCHE : la FDA homologue Evrysdi contre l'amyotrophie musculaire spinale
03:34aRoche steigt mit US-Zulassung für Evrysdi (Risdiplam) in SMA-Rennen ein
01:38aRoche erhält US-Zulassung für Muskelschwund-Medikament
08/07Aktien New York Schluss: Tech-Anleger lassen nach Rekord-Rally Dampf ab
More news
Stock Trading Strategies
BIOGEN INC. - 08/07
Buying pressure
BUY
More Stock Trading Analysis
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 310,68 $
Last Close Price 305,71 $
Spread / Highest target 27,2%
Spread / Average Target 1,63%
Spread / Lowest Target -25,4%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.3.03%48 398
CSL LIMITED-0.57%89 334
SAMSUNG BIOLOGICS CO.,LTD.77.37%42 742
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.224.31%36 982
WUXI BIOLOGICS (CAYMAN) INC.72.33%29 772
UCB46.05%23 083